rizatriptan benzoate

This page contains recent news articles, when available, and an overview of rizatriptan benzoate but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.

Overview:

rizatriptan benzoate (when available)

Pharmacology and use:
Rizatriptan is a selective 5-hydroxytryptamine receptor subtype agonist indicated for the acute treatment of migraine attacks with or without aura in adults. Rizatriptan is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine. Rizatriptan is an agonist for a vascular 5-hydroxytryptamine receptor subtype (probably a member of the 5-HT_1D family) having only a weak affinity for 5-HT_1A, 5-HT_5A, and 5-HT₇ receptors and no significant affinity or pharmacological activity at 5-HT₂, 5-HT₃ or 5-HT₄ receptor subtypes or at alpha1-, alpha2-, or beta-adrenergic, dopamine1,; dopamine2; muscarinic, or benzodiazepine receptors. This action in humans correlates with the relief of migraine headache. In addition to causing vasoconstriction, experimental data from animal studies show that Rizatriptan also activates 5-HT₁ receptors on peripheral terminals of the trigeminal nerve innervating cranial blood vessels, which may also contribute to the antimigrainous effect of Rizatriptan in humans. For treatment of acute migraine attacks.

Mechanism Of Action:
Rizatriptan binds with high affinity to human 5-HT_1B and 5-HT_1D receptors leading to cranial blood vessel constriction.

News Articles on Rizatriptan

Teva Gets Tentative Approval for Generic Maxalt  -  Apr 25, 2008
Maxalt (rizatriptan benzoate) was approved by the FDA in 1998 for the short-term treatment of migraine attacks in adults. Final approval of the generic is ... FDA news - FDA news (subscription)

CPAP May Help Headaches  -  Sep 11, 2005
The patient was also treated with 5 mg of zolmitriptan four times a month during acute attacks, and 10 mg of rizatriptan benzoate was also given as an ... Sleep Review

Federal Register 2007 - 72 FR 30386 Draft Guidances for Industry …  -  May 31, 2007
Calcium Chloride Risedronate Sodium Risperidone Ritonavir Rizatriptan Benzoate Rosiglitazone Maleate Rosuvastatin Calcium S Sertraline HCl Sibutramine ... Pay-Per-View - Federal Register 2007 - Loislaw

Press Release: Progressive Following on Teva Pharmaceutical Industries...  -  Apr 17, 2008
...(ANDA) to market its generic version of Merck's migraine pain treatment Maxalt (Rizatriptan Benzoate) Tablets, equivalent to 5 mg and 10 mg base. ... Pay-Per-View - M2 Presswire - HighBeam Research

Psoriasis drug.(drug approvals)(Brief article) | Article from Chain...  -  Oct 23, 2006
MERCK AND CO. INC. Active Ingredient(s): RIZATRIPTAN BENZOATE O-T-C/RX Status: RX Indication(s): Acute treatment of migraine ... Pay-Per-View - Chain Drug Review - HighBeam Research

제목 : 요양급여 고시개정(안)(5/16)  -  May 17, 2007
...�?한 rizatriptan benzoate(품명 맥살트멜트구강정 10mg) 등 14항목�?� �?�번 개정안�?� 통해 급여�?서 삭제�?�다. 복지부 보험약제팀�?� “�?�번 개정안�? 별�?��?� �?�견�?� ... 메디�?�뉴스

Teva Pharmaceutical Industries Ltd. получила предварительное …  -  Apr 21, 2008
Также компани�? получила предварительное разрешение FDA на маркетинг препарата Rizatriptan Benzoate в форме таблеток по 5 и 10 мг, дженерикового аналога ... Фармацевтиче�?кий ве�?тник

Brand Names/Synonyms:
rizatriptan benzoate is also known by the following brand names and/or synonymsCHEMBANK1748; MK-0462; Maxalt; Maxalt-Mlt; Mk 462 Free Base; Risatriptan; Rizatriptan; Rizatriptan Benzoat; Rizatriptan Benzoate

Drug Category:
rizatriptan benzoate is categorized under the following by the FDA: Anti-migraine Agents; Vasoconstrictor Agents; Anti-inflammatory Agents; Selective Serotonin Agonists; ATC:N02CC04

Dosage Forms:
WAFER

Absorption:
90%, with oral

Interactions:
[an error occurred while processing this directive]

Chemical IUPAC Name:
N,N-dimethyl-2-[5-(1H-1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]-ethanamine

Disclaimer:

Contact a physician with regard to health concerns. Email requests for further health information will be discarded.

The materials contained on this Web site are for informational purposes only and do not constitute health or medical advice. Use of information on this site does not create or constitute any kind of agreement or contract between you and the owners or users of this site, the owners of the servers upon which it is housed, or anyone else who is in any way connected with this site.

Many links on cancernewsnetwork.org lead to other sites. cancernewsnetwork.org does not sponsor, endorse or otherwise approve of the materials appearing in such sites. Nor is CancerNewsNetwork.org responsible for dead or misdirected links.

IF YOU NEED A LINK OR TEXT REMOVED FROM THIS PAGE PLEASE CONTACT cancernewsnetwork (at) live.com.
We will do our best to accommodate your request.